BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

In addition to its deal with Penn, BioNTech also reached a $791.5 million settlement to resolve a dispute under which the U.S. government said it was owed in royalty payments from the licensing ...

Upon partial receipt of the Settlement Payment, Penn has agreed to dismiss with prejudice the litigation Penn filed against the Company and its former subsidiary, BioNTech RNA Pharmaceuticals ...

(Reuters) -BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its ...

The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

(Reuters) -BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its ...

In a regulatory filing, BioNTech (BNTX) said ... On December 20, 2024, the Company entered into a settlement agreement with the NIH. Under the terms of the Settlement Agreement, the Company ...

Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit filed by the university over royalty claims related to the COVID-19 shot. The deal ...